Encompass Health (NYSE:EHC – Get Rating) had its price target lowered by stock analysts at Truist Financial from $85.00 to $75.00 in a report released on Tuesday, The Fly reports. Truist Financial’s price objective would suggest a potential upside of 32.96% from the stock’s current price.
Other analysts have also issued research reports about the company. StockNews.com lowered Encompass Health from a “buy” rating to a “hold” rating in a report on Friday, June 10th. TheStreet upgraded Encompass Health from a “c+” rating to a “b-” rating in a report on Tuesday, March 15th. Royal Bank of Canada lowered their target price on Encompass Health from $85.00 to $82.00 in a report on Wednesday, June 8th. Stephens lowered their target price on Encompass Health from $78.00 to $74.00 in a report on Tuesday. Finally, Credit Suisse Group cut their price target on Encompass Health from $83.00 to $82.00 and set an “outperform” rating on the stock in a research report on Friday, June 10th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $79.56.
Shares of NYSE EHC opened at $56.41 on Tuesday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.26. The firm has a market capitalization of $5.63 billion, a price-to-earnings ratio of 14.43, a PEG ratio of 1.88 and a beta of 0.96. The stock has a 50 day moving average price of $64.98 and a 200 day moving average price of $65.41. Encompass Health has a 52-week low of $53.56 and a 52-week high of $85.75.
Encompass Health (NYSE:EHC – Get Rating) last announced its quarterly earnings results on Wednesday, April 27th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.32 billion. Encompass Health had a return on equity of 17.99% and a net margin of 7.51%. Encompass Health’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.05 earnings per share. Analysts forecast that Encompass Health will post 4.09 earnings per share for the current year.
In other news, Director Kevin J. O’connor bought 1,000 shares of Encompass Health stock in a transaction dated Friday, May 6th. The stock was acquired at an average cost of $66.48 per share, with a total value of $66,480.00. Following the acquisition, the director now owns 3,436 shares of the company’s stock, valued at $228,425.28. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 2.70% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of EHC. Morgan Stanley increased its position in Encompass Health by 27.5% during the 2nd quarter. Morgan Stanley now owns 670,104 shares of the company’s stock worth $52,288,000 after purchasing an additional 144,463 shares during the period. HighTower Advisors LLC increased its position in Encompass Health by 18.6% during the 3rd quarter. HighTower Advisors LLC now owns 3,857 shares of the company’s stock worth $290,000 after purchasing an additional 605 shares during the period. Franklin Resources Inc. increased its position in Encompass Health by 74.6% during the 3rd quarter. Franklin Resources Inc. now owns 4,661 shares of the company’s stock worth $350,000 after purchasing an additional 1,992 shares during the period. Gotham Asset Management LLC acquired a new position in Encompass Health during the 3rd quarter worth approximately $279,000. Finally, MML Investors Services LLC increased its position in Encompass Health by 11.9% during the 3rd quarter. MML Investors Services LLC now owns 6,638 shares of the company’s stock worth $498,000 after purchasing an additional 706 shares during the period. 91.70% of the stock is owned by hedge funds and other institutional investors.
About Encompass Health (Get Rating)
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Further Reading
Receive News & Ratings for Encompass Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
